
CYTX
Other · Other · $4.6M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2018
EPS trend, 90 days to now · +14.3% over 90 days · 30-day revisions 2 up, 0 down
Beat estimates in 0 of the last 3 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 14, 2018 | Time not confirmed | — | -0.55 | — |
| Aug 14, 2018 | Time not confirmed | -0.45 | -0.59 | -31.1% |
| Mar 8, 2018 | Time not confirmed | -0.50 | -1.00 | -100.0% |
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in developing treatments for cancer and other diseases in the United States. The company's lead product candidate in pipeline is DocePLUS, an albumin-stabilized PEGylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. It also engages in developing DoxoPLUS, an injectable generic PEGylated liposomal formulation…